Centro Diagnóstico Boris Berenstein has been acquired by DASA
The Berenstein family has sold Centro Diagnóstico Boris Berenstein (CDBB) to Diagnósticos da America S.A. (DASA).
CDBB is among the most respected and well-known diagnostic imaging services in the Brazilian northeast region, focusing on MRIs, TC scans and ultrasound exams. It has six patient service centers, distributed in four different cities in the Recife metropolitan region.
DASA is one of the leading healthcare companies in Brazil, operating the biggest diagnostics business in LatAm with a nation-wide network of high-complexity hospitals, clinics, oncology centers and other healthcare management services. DASA serves more than 20 million patients every year and has around 40,000 employees and 250,000 hired physicians.
One of Oaklins’ teams in Brazil acted as the exclusive financial advisor to the seller and the management of CDBB in the preparation of the sale process and due diligence, the approach and parallel negotiations with potential buyers, and assisted them until closing.
Boris Berenstein
Former Owner and President, Centro Diagnóstico Boris Berenstein
Talk to the deal team
Denis Morante
Oaklins Fortezza Partners
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more